290 patents
Page 6 of 15
Utility
Tangential Viral Filtration
24 Mar 22
Viral filters include a filter member featuring a first surface and a second surface and having a thickness extending between the first and second surfaces in a first direction, and a plurality of channels formed in the filter member, each of the channels having a channel axis, where during use, a solution carrying a viral load flows in a direction parallel to the first surface, and at least a portion of the viral load enters the membrane through the first surface and propagates in the first direction, and where for at least 50% of the channels in the filter member, the channel axis is oriented at an angle of between 5 degrees and 85 degrees relative to the first direction.
Tarl Vetter, Kevin Brower
Filed: 7 Dec 21
Utility
Site-specific Antibody-drug Conjugation Through Glycoengineering
24 Mar 22
The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide.
Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
Filed: 17 Aug 21
Utility
Oligosaccharide-protein conjugates
22 Mar 22
Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI.
Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
Filed: 24 Sep 19
Utility
SERPINC1 iRNA Compositions and Methods of Use Thereof
17 Mar 22
The invention relates to pharmaceutical compositions comprising an iRNA agent, e.g., double stranded ribonucleic acid (dsRNA) agent and methods of using such compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).
Akin Akinc
Filed: 16 Jan 20
Utility
Integrated Continuous Isolation of Fluid Streams From Sterile Process Vessels
17 Mar 22
Provided herein are isolation processes and the associated hardware to allow fluid streams to be isolated from a sterilized system (e.g., a sterile process vessel) that contains a sterile process.
Robert Snow
Filed: 24 Nov 21
Utility
Colony stimulating factor-1 receptor (CSF-1R) inhibitors
15 Mar 22
John L. Kane, Jr., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Wai-Kwok Shum, Linli Wei
Filed: 19 Jul 16
Utility
Glucosylceramide Synthase Inhibitors
10 Mar 22
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
Elyse BOURQUE, Mario A. CABRERA-SALAZAR, Cassandra CELATKA, Seng H. CHENG, Bradford HIRTH, Andrew GOOD, Katherine JANCSICS, John MARSHALL, Markus METZ, Ronald K. SCHEULE, Renato SKERLJ, Yibin XIANG, Zhong ZHAO, John LEONARD, Thomas NATOLI, Elina MAKINO, Herve HUSSON, Oxana BESKROVNAYA
Filed: 14 Apr 21
Utility
Perfusion Bioreactor With Filtration Systems
10 Mar 22
The disclosure provides a filtration system for a cell culture apparatus and a method of cell culture.
Jiuyi Lu, Jason Walther, Jonathan Wang, Kevin Victor Chen
Filed: 11 Nov 21
Utility
Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
8 Mar 22
Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine.
Pradeep K. Dhal, Robert J. Miller, Steven C. Polomoscanik, Philip Just Larsen, Thomas Huebschle, Thorsten Schmidt, Ian Davison, Peter D. McDonnell, Chinyere Agbugba
Filed: 16 Dec 15
Utility
Fusion Proteins Comprising PDGF and Vegf Binding Portions and Methods of Using Thereof
3 Mar 22
The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins.
Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
Filed: 2 Jul 21
Utility
Recombinant Glycoproteins and Uses Thereof
3 Mar 22
Provided herein are recombinant glycoproteins (e.g., recombinant human α-galactosidase-A proteins) with an altered (e.g., improved) glycosylation profile, and pharmaceutical compositions and kits including one or more of these proteins.
Karen Lee, Christopher Hwang, Christine DeMaria
Filed: 22 Sep 21
Utility
Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
1 Mar 22
Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described.
Guang Qu, John Fraser Wright
Filed: 12 Aug 19
Utility
Gene Therapy for Retinitis Pigmentosa
24 Feb 22
Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708.
Catherine O'RIORDAN, Matthew ADAMOWICZ
Filed: 22 Jul 21
Utility
FGFR3 Antibodies and Methods of Use
24 Feb 22
Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided.
Yves SABBAGH, Yangde CHEN, William BRONDYK, Huawei QIU, Sunghae PARK, Ronnie WEI, Yu QIU, Yanfeng ZHOU, Cendrine LEMOINE, HyunSuk CHO
Filed: 20 Aug 21
Utility
Slow intraventricular delivery
22 Feb 22
Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier.
James C. Dodge, Marco A. Passini, Lamya S. Shihabuddin, Seng H. Cheng
Filed: 21 Feb 19
Utility
Humanized anti-complement factor Bb antibodies
8 Feb 22
Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.
Graham Parry, Stephen Moore, Michael Storek, Nina C. Leksa
Filed: 19 Apr 21
Utility
Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline
3 Feb 22
The present invention relates to chemical processes for the manufacture of certain quinazoline derivatives, or pharmaceutically acceptable salts thereof.
Jorgen Blixt, Michael David Golden, Philip John Hogan, David Michael Glanville Martin, Francis Joseph Montgomery, Zakariya Patel, John David Pittam, George Joseph Sependa, Christopher John Squire, Nicholas Cartwright Alexander Wright
Filed: 2 Nov 20
Utility
Methods for enhanced removal of impurities during protein A chromatography
1 Feb 22
Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and/or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.
Carl A. Beigie
Filed: 20 Dec 18
Utility
Methods for Treating Symptoms and Disorders Associated with Lysosomal Storage Diseases
27 Jan 22
This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with lysosomal storage diseases using quinuclidine compounds of formula (I), optionally in combination with enzyme replacement therapy.
Nigel Patrick Somerville CRAWFORD, Tanya Zaremba FISCHER
Filed: 3 Feb 20
Utility
Pharmaceutical Compositions Comprising Venglustat
27 Jan 22
The present disclosure relates to pharmaceutical compositions, including dosage forms, such as tablets or capsules, comprising venglustat, in free base, or pharmaceutically acceptable salt form, a diluent/filler and a lubricant, optionally in combination with one or more additional therapeutic agents, to processes for manufacture thereof, and to methods of use in the treatment or prevention of disease.
Audrey JEANJEAN, Danielle COMBESSIS, David RIGAL, Chris HO, Pankaj TANEJA
Filed: 23 Jul 21